News – Page 1109 – Endpoints News

CheckMate-227: Bristol-Myers Squibb has a MYSTIC-sized problem on its hands

8 years ago

GSK's Moncef Slaoui joins the board at Moderna; Aduro promotes van Elsas to CSO

8 years ago

J&J sews up an expanded vaccine pact with Bavarian Nordic, paying $43M for HIV, hep B projects

8 years ago

Intellipharmaceutics shares crushed as FDA experts snub pain drug; Moncef Slaoui joins Moderna board

8 years ago

Tesaro partners with Takeda in Asia, bagging a $340M deal for Zejula

8 years ago

Alexion joins the R&D reorganization gala, pruning a slate of projects and revving up new deals

8 years ago

Sienna Bio bags $65M in the latest successful biotech IPO

8 years ago

Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech

8 years ago

AstraZeneca inks $8.4B pact with Merck as crucial MYSTIC study fails and shares plunge

8 years ago

Eagle Pharma shares tank after FDA stiff-arms its application for heat stroke remedy

8 years ago

Kezar bags a $50M B round in wake of PhIa study; Bayer kicks back a partnered drug

8 years ago

Dynavax shares slide as FDA review spotlights a hazy safety issue for Heplisav

8 years ago

Tetraphase lines up a new FDA pitch for antibiotic after it comes through in latest PhIII

8 years ago

GSK CEO Walmsley is reorganizing R&D, dropping drugs and adding a new focus on cancer research

8 years ago

British billionaire Jim Mellon and high-profile partners roll the dice on an anti-aging upstart

8 years ago

Gottlieb to delay issuing layoff notices and reassures FDA staff that Congress will reauthorize user fees

8 years ago

Canaan reels in a jumbo $800M fund with a big focus on a new wave of biotech startups

8 years ago

Sarepta raising $325M; Astellas joins the big migration to Cambridge, MA

8 years ago

Neuralstem’s lead drug crumbles in PhII, adding to a litany of failures for depression drugs and blasting shares

8 years ago

Riders on the storm: VenatoRx bags a $42M round to back antibiotics pipeline

8 years ago

Biogen lays out a plan to “streamline” ops, add $400M to fund neurosciences R&D, new deals

8 years ago

Restructuring the pipeline, Eli Lilly says a baricitinib comeback in rheumatoid arthritis could take years

8 years ago

Lilly, J&J, AbbVie and WuXi help seed a regenerative medicine upstart

8 years ago

Novavax makes a case for a do-over on its failed RSV vaccine — but it's an uphill climb

8 years ago

First page Previous page 1106 1107 110811091110 1111 1112 Next page Last page